Management Team

Dr. Weidanz brings over twenty years of experience in biotechnology with an emphasis in immunology, immunotherapy and immunodiagnostic product development. In addition to Receptor Logic, Inc., he co-founded two other biotech companies and serves as a scientific board member for one company. He has a breadth of experience in research management, technology commercialization and product development. Dr. Weidanz formed Receptor Logic in 2003 and has since served as its principal scientist. He also is the founding active Director for the Center for Immunotherapeutic Research and is a tenured associate professor at Texas Tech University Health Science Center. As Center Director he is responsible for building an interactive group of researchers to develop novel immunotherapeutics. Prior to his academic appointment and Receptor Logic, Dr. Weidanz was co-founder and Principal Scientist at Sunol Molecular Corporation, where he created and managed the T cell receptor (TCR) technology. Before starting Sunol Molecular, Dr. Weidanz worked for Baxter Diagnostics as a research scientist having as his primary responsibility the establishment of several protein expression systems that included bacteria, insect cells and mammalian cells. In addition, he was involved in assay development and contributed to the development of immunodiagnostic assays for cardiac markers and infectious diseases.

Dr. Weidanz has been honored with six awards from Texas Tech University Health Sciences Center since 2003, has been an invited speaker to over 50 national and international technical conferences, has 13 pending or issued patents, has numerous journal publications, and a book chapter. Further, Dr. Weidanz has received $19M in awards for a variety of research pursuits including the NIH and NIST.

He earned his B.S. (Biology) from West Virginia University, and both his M.P.H. (Epidemiology) and Ph.D. (Molecular and Cellular Biology) from the University of Alabama at Birmingham.

As Vice President of Business Development at Emergent Technologies, Dr. Pogue is responsible for evaluating the commercial potential of new technologies, determining both technical and market trajectories, and building partnerships to effectively commercialize products. Dr. Pogue brings over twenty years of experience in biologic development, spanning research management, biologic regulation, and intellectual property development and licensing. Dr. Pogue most recently served as Licensing Associate for the University of Texas at Austin where he negotiated licenses with companies ranging from newly formed startups to Fortune 500 enterprises.

Before coming to Texas, Dr. Pogue served as Vice President of Research and Development at Large Scale Biology Corporation (LSBC), where he managed a broad development program involving product development and preclinical and clinical testing of numerous lead compounds, including two receiving Orphan Drug Designation from the US FDA and 16 successfully completing early clinical trials. He also developed licensing and R&D contracts with corporate, academic, and government entities and supervised collaborative research relationships. Before joining LSBC, Dr. Pogue worked in the U.S. FDA's Center for Biologics Research and Evaluation as a scientist with Investigational New Drug and Biological Licensing Application review responsibilities. He holds a B.S. from Midwestern State University and a Ph.D. from Texas A&M University. Pogue has published numerous original scientific articles and reviews, is an inventor on multiple U.S. patents, and is a frequent invited speaker at national and international scientific meetings.